NCT06047509 is a NA clinical trial of Focal Laser Ablation in Prostate Cancer, sponsored by Jonsson Comprehensive Cancer Center.

Who is sponsoring NCT06047509?

NCT06047509 is sponsored by Jonsson Comprehensive Cancer Center.

What drugs are being tested in NCT06047509?

Interventions in NCT06047509: Focal Laser Ablation.

What condition does NCT06047509 study?

NCT06047509 studies Prostate Cancer.

Is NCT06047509 still recruiting?

NCT06047509 is currently terminated. Last updated 25 February 2026.

Last reviewed 2026-02-25 · How we verify

NCT06047509

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Focal Laser Ablation of Prostate Cancer: A Feasibility Study Using MRI/US Image Fusion for Guidance

Terminated NA Last updated 25 February 2026

What this trial tests

NA trial testing Focal Laser Ablation in Prostate Cancer in 2 participants. Terminated before completion.

Timeline

14 September 2023

Primary endpoint
13 January 2026

13 January 2026

Quick facts

Lead sponsor	Jonsson Comprehensive Cancer Center
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	14 September 2023
Primary completion	13 January 2026
Estimated completion	13 January 2026
Sites	1 location across United States

Drugs / interventions tested

Focal Laser Ablation

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Jonsson Comprehensive Cancer Center — full company profile →

Who can join

Adults 40 to 85, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label feasibility/pilot study to evaluate the safety and feasibility of the FocalPoint System with UnfoldAI. In this study, the investigators intend to use the UnfoldAI software to identify cancer margins and create ablation treatment plans and use the FocalPoint System to deploy and monitor thermal energy in cancerous regions of the prostate. Subjects will be assessed at 1 week, 1 month, and every 3 months until one-year post-FLA treatment(s) to be monitored for adverse events and complete quality-of-life questionnaires.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A narrative clinical trials review in the realm of focal therapy for localized prostate cancer.
Lazarovich A, Viswanath V, Dahmen AS, Sidana A. · · 2024 · cited 4× · PMID 39697719 · DOI 10.21037/tcr-23-2406

Verify or expand the search:

Other trials of Focal Laser Ablation

Trials testing the same drug.

NCT04305925 — Focal Laser Ablation of Prostate Cancer · EARLY_PHASE1 · active not recruiting
NCT02357121 — Focal Laser Ablation of Prostate Tissue · EARLY_PHASE1 · completed

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Jonsson Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06047509 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
Last refreshed: 25 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06047509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing